2014


To access this material please log in or register

Register Authorize
2014/№2

Role of ivabradine (Koraxane) in therapy of chronic heart failure

Grishkin Yu.N.

Keywords: Coraxan, treatment, CHF

DOI: 10.18087 / rhfj.2014.2.1936

The review is focused on new option of drug therapy for CHF using ivabradine, a specific cardiomyocyte If -channel blocker.
  1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93 (9):1137–1146.
  2. Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распростра­ненность хронической сердечной недостаточности в Европей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):112–115.
  3. Беленков Ю. Н., Агеев Ф. Т., Мареев В. Ю. Парадоксы сердечной недостаточности: взгляд на проблему на рубеже веков. Сердечная недостаточность. 2000;1 (1):4–6.
  4. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314 (24):1547–1552.
  5. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V–HeFT III. Vasodilator – Heart Failure Trial (V–HeFT) Study Group. Circulation. 1997;96 (3):856–863.
  6. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  7. DiFrancesco D. Block and activation of the pacemaker channel in calf purkinje fibres: effects of potassium, caesium and rubidium. J Physiol. 1982 Aug;329:485–507.
  8. Harron DW, Jady K, Riddell JG, Shanks RG. Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol. 1982 Mar-Apr;4 (2):213–20.
  9. Gross GJ, Daemmgen JW. Beneficial effects of two specific bradycardic agents AQ-A39 (falipamil) and AQ-AH 208 on reversible myocardial reperfusion damage in anesthetized dogs. J Pharmacol Exp Ther. 1986 Aug;238 (2):422–8.
  10. Frishman WH1, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. J Am Coll Cardiol. 1995 Aug;26 (2):305–12.
  11. David A. Saint. The Role of Cardiac Pacemaker Currents in Antiarrhythmic Drug Discovery. Cardiac Drug Development Guide. Edited by: M. K. Pugsley © Humana Press Inc, Totowa, NJ. –2003. –431 р. –Р. 34–38.
  12. Recommendations of the Task Force of the ESC. Eur Heart J. 2006;27 (11):1341–1381.
  13. Tendera M, Borer JS, Tardif JC. Efficacy of I (f) inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology. 2009;114 (2):116–25.
  14. Tardif JC, Ford I, Tendera M et al. Efficacy of ivabradine, a new selective if inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26 (23):2529–2536.
  15. Карпов Ю. А. Программа АЛЬТЕРНАТИВА – исследование антиангинальной эффективности и переносимости Кораксана (ивабрадина) и оценка качества жизни пациентов со стабильной стенокардией. Сердце. 2007:2 (6):102–104.
  16. Koester R, Kaehler J, Ebelt H et al. Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol. 2010;99 (10):665–672.
  17. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008;372 (9641):817–821.
  18. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101 (6):865–869.
  19. Diaz A, Bourassa M, Guertin M, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26 (10):967–974.
  20. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27 (1):65–75.
  21. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376 (9744):875–885.
  22. Bohm M, Swedberg K, Komajda M et al. on behalf of the SHIFT investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet. 2010;376 (9744):886–894.
  23. Custodis F1, Reil JC, Laufs U, Böhm M. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013 Sep;62 (3):183–7.
  24. Borer JS, Bohm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chro­nic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33 (22):2813–2820.
  25. Komajda M, Böhm M, Borer J et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and low blood pressure in the SHIFT trial. Eur Heart J. 2013;34 (Suppl 1):610.
  26. Ford I, Robertson M, Borer J et al. The top ten factors related to morbidity and mortality in patients with chronic heart failure and LVSD: a SHIFT prognostic model. Eur Heart J. 2013;34 (Suppl1):286.
  27. Tavazzi L, Swedberg K, Komajda M et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: efficacy and safety of Ivabradine. a SHIFT study analysis. Eur Heart J. 2013;34 (Suppl 1):652.
  28. Swedberg K, Komajda M, Bohm M et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59 (22):1938–1945.
  29. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная недостаточность. 2013;14 (7): 379–472.
  30. Bohm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102 (1):11–22.
  31. Dickstein K, Cohen-Solal A, Filippatos G et al; ESC Committee for Practice Guidelines (CPG) / ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10 (10):933–989.
Grishkin Yu.N. Role of ivabradine (Koraxane) in therapy of chronic heart failure. Russian Heart Failure Journal. 2014;83 (2):121–125

To access this material please log in or register

Register Authorize
Ru En